At what pace is the siliq market growing, and what is its estimated value?
The siliq market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to a rise in psoriasis prevalence, an increase in total diagnosed prevalence, an increase in the global prevalence of chronic HF, an increase in the prevalence of skin disease, and increasing adoption of biologic therapies.
The siliq market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to an increasing trend of online shopping among patients, growing patient demand for higher living standards, growing interest in combination therapies, increasing success in clinical trials, and rising telemedicine utilization. Major trends in the forecast period include technological advancements in delivery systems, innovative products and technologies, a shift towards personalized medicine, advanced marketing strategies utilizing digital platforms, and the technological development of AI-based tools.
Get Your Free Sample of The Global Siliq Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20265&type=smp
What are the top drivers to the rising demand in the siliq market?
The increase in the prevalence of skin disease propels the growth of the siliq market going forward. Skin disease refers to a broad range of conditions that affect the skin’s structure, function, or appearance, often caused by infections, inflammation, genetic factors, autoimmune disorders, or environmental influences. The increase in the prevalence of skin disease is attributed to factors such as environmental changes, rising pollution levels, increased sun exposure, genetic predispositions, and lifestyle factors like poor diet and stress. Siliq is beneficial for skin disease, particularly moderate to severe plaque psoriasis, as it targets specific immune system pathways to reduce inflammation, improve skin appearance, and alleviate symptoms such as redness, scaling, and itching. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization focused on cancer elimination, projected 108,270 reported cases of skin cancer, marking a 3.2% increase from the 104,930 cases recorded in 2023. Therefore, the increase in the prevalence of skin disease is fueling the growth of the siliq market.
How is the siliq market segmented?
The siliq market covered in this report is segmented –
1) By Clinical Indication: Moderate To Severe Plaque Psoriasis; Other Indications
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies
3) By End-User: Hospitals; Specialty Clinics; Home Care Settings
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/siliq–global-market-report
Who are the top competitors in the siliq market?
Major companies operating in the siliq market are Valeant Pharmaceuticals International Inc.
What significant trends should we anticipate in the siliq market over the forecast period?
Which regional trends are influencing the siliq market, and which area dominates the industry?
North America was the largest region in the siliq market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the siliq market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Siliq Market Report 2025 Offer?
The siliq market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Siliq refers to a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The mechanism of action involves its targeting and inhibition of the IL-17A receptor. IL-17A is a pro-inflammatory cytokine that plays a crucial role in the development of inflammation in conditions like plaque psoriasis.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20265
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
